News About: Pharm. Industry


War of words between prosecution and defendant over former witness’s testimony

The prosecution and the defense counsel had a tense war of nerves over questioning the former Novartis employee, who accepted provision of rebates via specialized magazines and service companies. The Criminal Departm...

What is the main reason for low profitability of multinational pharma?

It was observed the multinational pharmaceutical companies’ sales cost rate reached 70%. The ratio was higher than the one of Korean pharmaceutical companies, 60%. It was criticized, that is, the reason why they have...

MSD Korea’s antibody, Zerbaxa’s approval in Korea

‘Zerbaxa(generic name: ceftolozane+tazobactam),’ a MSD Korea’s(CEO Avi BenShoshan) new antibody, acquired sales approval in Korea. On the 7th, the Ministry of Food and Drug Safe...

Multinational pharmas with increased sales, but decreased profitability

Multinational pharmaceutical companies which branched in Korea recorded 7% higher sales, but decreased operating profits and net profits last year. According to the Yakup Shinmoon’s(www.yakup.com) analysis result of ...

BAI, “Hanmi truly delayed the report about ‘Olita,’ but no intention was found”

The Hanmi Pharm’s delayed report on the side effect of ‘Olita Tab’ was officially confirmed. According to audit result on the Hanmi Pharm’s clinical trial for Olita Tab, requested by the National Assembly, the Board ...

Regarding delayed report over Olita side effects, Hanmi will do best not to happen again

Regarding the Board of Audit and Inspection’s audit result that it took 14 months for the SJS(Stevens-Johnson syndrome) occurrence to be reported to the Ministry of Food and Drug Safety(MFDS), Hanmi Pharm explained “T...

2 of 3 innovative pharmas record operating profit ratio less than 10%

It was observed the innovative pharmaceutical companies’ operating profit ratio was weakened. According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 47 innovative pharmaceutical companies’ 2016 audit rep...

Pharma & Bio-pharma will revitalize with relieved anxiety and devotion to R&D

The pharmaceutical field will revitalize. The unexpected incident at the end of the last year continued until the beginning of this year, but it seems it is going to be settled soon, which energizes the industry. It...

KPDS, “Novartis’ illegality is clear… it is time to explain generics’ safety to patients”

The Korean Pharmacists for Democratic Society(KPDS) urged prompt and strict administrative measures for the Novartis Korea’s rebate case. In the statement on the 12th, the KPDS announced the Ministry of Health and We...

Prosecution’s fierce strike on HIRA over pharmas’ provision of rebates

The prosecution has strongly pressured pharmaceutical companies and wholesalers. It has omnidirectionally target all the organization related to rebate. According to the industry concerned, the Eastern Branch of Busa...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.